TY - JOUR
T1 - CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
AU - Pasvolsky, Oren
AU - Daher, May
AU - Alatrash, Gheath
AU - Marin, David
AU - Daver, Naval
AU - Ravandi, Farhad
AU - Rezvani, Katy
AU - Shpall, Elizabeth
AU - Kebriaei, Partow
N1 - Publisher Copyright:
Copyright © 2022 Pasvolsky, Daher, Alatrash, Marin, Daver, Ravandi, Rezvani, Shpall and Kebriaei.
PY - 2022/1/10
Y1 - 2022/1/10
N2 - Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet need. Building on growing knowledge of the interactions between leukemic cells and their bone marrow microenvironment, strategies to battle AML by immunotherapy are under investigation. In the current review we describe the advances in immunotherapy for AML, with a focus on chimeric antigen receptor (CAR) T cell therapy. CARs constitute powerful immunologic modalities, with proven clinical success in B-Cell malignancies. We discuss the challenges and possible solutions for CAR T cell therapy development in AML, and examine the path currently being paved by preclinical and clinical efforts, from autologous to allogeneic products.
AB - Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet need. Building on growing knowledge of the interactions between leukemic cells and their bone marrow microenvironment, strategies to battle AML by immunotherapy are under investigation. In the current review we describe the advances in immunotherapy for AML, with a focus on chimeric antigen receptor (CAR) T cell therapy. CARs constitute powerful immunologic modalities, with proven clinical success in B-Cell malignancies. We discuss the challenges and possible solutions for CAR T cell therapy development in AML, and examine the path currently being paved by preclinical and clinical efforts, from autologous to allogeneic products.
KW - acute myeloid leukemia
KW - allogeneic
KW - cancer immunotherapy
KW - chimeric antigen receptor T cells
KW - immune effector cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85123375229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123375229&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.800110
DO - 10.3389/fonc.2021.800110
M3 - Review article
C2 - 35083154
AN - SCOPUS:85123375229
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 800110
ER -